NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
30.41
-2.42 (-7.39%)
At close: Mar 3, 2026, 4:00 PM EST
31.48
+1.07 (3.54%)
Pre-market: Mar 4, 2026, 6:31 AM EST

NAMS Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-203.82-241.6-176.94-22.63-32.52
Depreciation & Amortization
0.220.110.010.010.02
Stock-Based Compensation
59.4333.6224.574.121.19
Other Adjustments
4.3881.975.2318.8-1.65
Changes in Accounts Payable
4.91-12.955.074.819.38
Changes in Accrued Expenses
2.451.695.47-8.68-
Changes in Unearned Revenue
-2.02-3.95-8.7118.43-
Changes in Other Operating Activities
-13.28-17.464.03-4.19-5.03
Operating Cash Flow
-147.78-158.56-141.2210.67-28.62
Capital Expenditures
-0.25-0.67-0.02-0.22-0.02
Purchases of Investments
-296.73-62.18---
Proceeds from Sale of Investments
122.06----
Investing Cash Flow
-174.92-62.85-0.02-0.22-0.02
Issuance of Common Stock
29.52660.58.91391.1678.46
Repurchase of Common Stock
--0.99---
Net Common Stock Issued (Repurchased)
29.52659.518.91391.1678.46
Other Financing Activities
---0.75-0.01
Financing Cash Flow
29.52659.518.91391.9178.45
Effect of Exchange Rate Changes on Cash and Cash Equivalents
12.76-6.85.055.251.62
Net Cash Flow
-293.18438.1-132.33402.3549.81
Free Cash Flow
-148.03-159.24-141.2410.44-28.64
FCF Margin
-657.82%-349.49%-1002.43%10.17%-
Free Cash Flow Per Share
-1.25-1.69-1.720.55-1.21
Levered Free Cash Flow
-211.79-274.83-171.08-12.47-28.18
Unlevered Free Cash Flow
-233.65-209.52-177.146.6-29.59
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q